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Abstract
Background: The cytokines interleukin-1 and tumor necrosis factor (TNF), and the cytokine
blocker interleukin-1 receptor antagonist, all have been demonstrated to enter the cerebrospinal
fluid (CSF) following peripheral administration. Recent reports of rapid clinical improvement in
patients with Alzheimer's disease and related forms of dementia following perispinal administration
of etanercept, a TNF antagonist, suggest that etanercept also has the ability to reach the brain CSF.
To investigate, etanercept was labeled with a positron emitter to enable visualization of its
intracranial distribution following peripheral administration by PET in an animal model.
Findings: Radiolabeling of etanercept with the PET emitter 64Cu was performed by DOTA
(1,4,7,10-tetraazadodecane-N,N',N",N"'-tetraacetic acid) conjugation of etanercept, followed by
column purification and 64Cu labeling. MicroPET imaging revealed accumulation of 64Cu-DOTA-
etanercept within the lateral and third cerebral ventricles within minutes of peripheral perispinal
administration in a normal rat anesthesized with isoflurane anesthesia, with concentration within
the choroid plexus and into the CSF.
Conclusion:  Synthesis of 64Cu-DOTA-etanercept enabled visualization of its intracranial
distribution by microPET imaging. MicroPET imaging documented rapid accumulation of 64Cu-
DOTA-etanercept within the choroid plexus and the cerebrospinal fluid within the cerebral
ventricles of a living rat after peripheral administration. Further study of the effects of etanercept
and TNF at the level of the choroid plexus may yield valuable insights into the pathogenesis of
Alzheimer's disease.
Background
Excess tumor necrosis factor-alpha (TNF) has been identi-
fied as a therapeutic target in Alzheimer's disease (AD)[1].
Excess TNF in the cerebrospinal fluid (CSF), at concentra-
tions 25 times higher than in controls, has been demon-
strated in AD, and may predict disease progression[2].
Etanercept is a recombinant dimeric fusion protein con-
sisting of the extracellular ligand-binding portions of two
human p75 TNF receptors linked to the Fc fragment of
human IgG1, which functions in vivo as a potent anti-TNF
therapeutic. Recent reports of rapid clinical improvement
in patients with AD and related disorders following the
perispinal administration of etanercept (MW = 150,000)
suggested that etanercept had the ability to penetrate into
the CSF in the brain in a therapeutically effective concen-
tration[3,4], an ability which recently had been demon-
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strated for another cytokine antagonist, interleukin-1
receptor antagonist (IL1-RA) (MW = 17,000)[5]. To inves-
tigate this possibility, etanercept was conjugated with
64Cu, using a method developed by one of the authors [6].
64Cu is a positron emitter. When attached to etanercept,
utilizing the chelating agent (1,4,7,10-tetraazadodecane-
N,N',N",N"'-tetraacetic acid (DOTA), a molecule is pro-
duced, 64Cu-DOTA-etanercept, whose anatomic distribu-
tion may be imaged using positron emission tomography
(PET)[6]. To examine the intracranial distribution of radi-
olabeled etanercept, microPET imaging of the brain of a
living rat following peripheral administration of 64Cu-
DOTA-etanercept was performed.
Methods
Animal studies were conducted in accordance with the
applicable protocols by the Stanford Animal Care Com-
mittee. Etanercept (Immmunex, Amgen) was commer-
cially purchased in powder form. Preparation of 64Cu-
(1,4,7,10-tetraazadodecane-N,N',N",N"'-tetraacetic acid
(DOTA)-etanercept was as previously described[6]. 150
microliters of 64Cu-DOTA-etanercept solution (ca. 1 mCi)
was injected overlying the cervical spine of a 250 g
Sprague-Dawley rat at the C 6–7 level using a 30 gauge
needle at a depth of 6 mm while the rat was anesthetized
with 2.5% isoflurane inhalation anesthesia. The rat was
then placed in the head down position by tail suspension
for three minutes, immediately followed by placement
horizontally in the bed of a microPET imaging scanner
(microPET R4 rodent model scanner, Siemens Medical
Solutions USA, Inc.) designed for 5-min static scans; the
scan was initated two minutes after placement in the scan-
ner bed and was performed from five to ten minutes after
etanercept administration. The rationale for this method
of peripheral administration is to deliver etanercept into
the cerebrospinal venous system, as previously dis-
cussed[3,4,7-9]. The images were reconstructed by a 2-
dimensional ordered-subsets expectation maximum
(OSEM) algorithm, and no correction was necessary for
attenuation or scatter correction.
Results
MicroPET imaging revealed accumulation of 64Cu-DOTA-
etanercept within the lateral and third cerebral ventricles
within minutes of peripheral perispinal administration,
with concentration within the choroid plexus and into the
CSF suggested by the microPET images (Figure 1). These
non-invasive PET results are quite analagous to the results
of previous autoradiographic studies utilizing [125I]
labeled TNF, IL-1, and IL1-RA which demonstrated CSF
penetration within the cerebral ventricles in mice follow-
ing peripheral administration of each of these large mole-
cules[10].
Discussion
The apparent ability of etanercept to traverse the BCSFB
and enter the CSF in the brain demonstrated in this exper-
iment suggests that etanercept joins interleukin 1-RA (IL1-
RA), interleukin-1 (IL-1) (MW = 17,000), and TNF (MW =
17,000 as a monomer; 51,000 as a soluble trimer) as large
molecules which penetrate into the cerebrospinal fluid in
the brain after peripheral delivery[5,10,11]. These find-
ings may have significant implications for the treatment
of certain brain disorders, including the use of IL1-RA for
the treatment of stroke and the use of etanercept for the
treatment of Alzheimer's disease[1,3-5,7].
Rapid delivery of etanercept into the CSF within the cere-
bral ventricles following peripheral delivery was subse-
quently confirmed in a separate, later experiment in
multiple rats performed at the University of British
Columbia in Vancouver begun several months following
the completion of this study performed at Stanford(man-
uscript in preparation)[1].
These results highlight the important functional differ-
ences between the blood-cerebrospinal fluid barrier
(BCSFB) and the blood-brain barrier (BBB)[12,13]. The
BBB, formed by tight junctions between the endothelial
PET image, transverse section, of a living rat brain following  perispinal extrathecal administration of 64Cu-DOTA-etaner- cept, imaged 5 to 10 minutes following etanercept adminis- tration Figure 1
PET image, transverse section, of a living rat brain 
following perispinal extrathecal administration of 
64Cu-DOTA-etanercept, imaged 5 to 10 minutes fol-
lowing etanercept administration. The pattern is con-
sistent with penetration of 64Cu-DOTA-etanercept into the 
cerebrospinal fluid in the lateral and third ventricles. Note 
the horizontal linear enhancement within the lateral ventri-
cles which is suggestive of accumulation of tracer within the 
choroid plexus.BMC Research Notes 2009, 2:28 http://www.biomedcentral.com/1756-0500/2/28
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cells of the brain capillaries, prevents the passage of essen-
tially all large molecules, i.e. those with a molecular
weight (MW) greater than approximately 500 dal-
tons[14]. The BCSFB, formed primarily by the epithelial
cells of the choroid plexus, appears to be more permeable
with respect to large molecules than the BBB[13]. Thus
IL1-RA, IL-1, TNF, and etanercept plausibly all enter the
CSF by traversing the BCSFB via the choroid
plexus[1,10,11]. Failure to image the cerebral ventricles by
either autoradiography or by using PET imaging, as in the
present experiment(Figure 1), may have led, in one
study[15], to a failure to detect delivery of large molecules
into the cerebrospinal fluid and the choroid plexus.
Delivery of etanercept to the choroid plexus (CP) may
have significant physiologic implications. The CP is the
source of synthesis of numerous molecules, including
cytokines and growth factors, including TNF, TGF-alpha,
TGF-beta, FGF2 and IGF-II[12,13,16]. Epithelial cells of
the choroid plexus are known to express TNF[17]. The CP
has been postulated to be centrally involved in the patho-
genesis of AD[12,13,16]. It is possible that etanercept
reaching the CP may have intrinsic effects on CP cellular
function and cytokine and growth factor synthesis.
Etanercept reaching the CP could have paracrine or auto-
crine effects on the CP, or potentially could affect the
parenchyma in the periventricular or additional brain
regions by endocrine-like bulk flow of CSF[12,13]. Addi-
tionally, etanercept reaching the CP and the CSF could
have glial effects[1]. Alteration of glial modulation of neu-
ronal function mediated by TNF, beginning within the
CP, could potentially produce widespread neuronal and
cortical effects[1,3,4].
The effect of intracerebroventricular delivery of anti-TNF
biologics has recently been examined in two experimental
models investigating AD mechanisms[18,19]. In the first
study, intracerebroventricular delivery of infliximab, an
anti-TNF monoclonal antibody, prevented the inhibition
of LTP at hippocampal CA1 synapses caused by intracere-
broventicular injection of beta-amyloid [18]. In the sec-
ond study, intracerebroventricular delivery of an anti-TNF
monoclonal antibody prevented the nitration of proteins
in the hippocampus and the impairment of recognition
memory in mice induced by beta-amyloid fragments[19].
The results of these additional experimental models,
along with the known involvement of the CP in cytokine
synthesis, suggest that rapid delivery of 64Cu-DOTA-
etanercept into the choroid plexus may provide a poten-
tial explanation for the rapid clinical improvement noted
following perispinal administration of etanercept in
AD[1,3,4]. TNF is known to be capable of producing syn-
aptic effects within minutes[20].
Further investigation regarding the mechanisms by which
etanercept enters the cerebral ventricles, presumably by
crossing the BCSFB are warranted. At this time the exact
mechanism by which this occurs at the CP is unknown. At
the CP, in addition to specific saturable transport systems
for selected large molecules, there also exists a less known
paracellular diffusion pathway, which hydrophilic solutes
may utilize to penetrate the CSF, diffusing between
choroidal epithelial cells rather than through them[13].
Intravascularly administered inulin polysaccaride (MW =
5,500), for example, has been demonstrated to reach the
CSF by this paracellular diffusion pathway across the
BCSFB at the CP[13,21,22]. Alternatively, it is possible
that etanercept is actively transported across the CP epi-
thelium. One may hypothesize that this could occur via a
"piggyback" mechanism, associated with the binding of
etanercept to TNF, while TNF is itself actively transported
across the CP epithelium[10,11]. This "piggyback" mech-
anism might be facilitated by the natural occurrence of cir-
culating trimers of TNF which would present more than
one binding site per ligand. This speculation will require
further study for definitive answers to emerge.
Additional literature supports the argument that the
choroid plexus and nearby ependymal regions may be
points of entry of macromolecules into the CSF, particu-
larly after head-down tilt. This literature includes the dem-
onstration that head-down tilt, even for as short as five
minutes, disrupts the blood-CSF barrier of rabbits, allow-
ing trypan blue to penetrate the CNS[23]; that choroid
plexus proteins are expressed/localized in the ventricle-
facing apical membrane and choroidal CSF production is
increased, shortly after head-down tilt accomplished by
hindlimb-suspension in rats[24]; and that macromole-
cules may gain access to the brain and CSF by extracellular
(non-BBB) routes[25]. It has previously been hypothe-
sized that macromolecules, such as antibodies directed
against amyloid beta protein and erythropoietin, may
exert CNS effects by passage into the brain via extracellular
pathways[25]. Etanercept is highly potent, and may have
significant physiologic effects at low concentration[26].
Further study will be necessary to clarify if etanercept dis-
tribution via extracellular pathways, in addition to effects
at the choroid plexus and in the CSF, contributes to the
physiologic effects observed after perispinal etanercept
administration in conditions such as Alzheimer's disease.
With respect to extrapolation of the results of the present
experiment to AD, an additional consideration is neces-
sary. The experimental model used in the present study
included only normal animals, but changes in CP physi-
ology and barrier function may accompany both aging
and AD, and these changes could further influence the
passage of etanercept across the BCSFB[12,13,16,27]. In
the clinical studies of perispinal etanercept in AD, Trende-BMC Research Notes 2009, 2:28 http://www.biomedcentral.com/1756-0500/2/28
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lenburg head-down positioning is utilized following cer-
vical perispinal injection, hypothesized to increase access
of etanercept to the choroid plexus via the cerebrospinal
venous system[1,4,9]. It is hypothesized that head-down
positioning, by increasing venous pressure in the CP, may
have the potential to influence transport across the BCSFB
or across the ependyma or the circumventricular organs
into the periventricular brain parenchyma[1,4,23,28].
Effects of tail suspension on ependymal ultrastructure
have recently been reported[29]. Further study is needed
to confirm this hypothesis.
The limited time of brain imaging, 10 minutes after
etanercept administration in this study, does not allow a
definitive statement regarding later parenchymal delivery.
Future studies will reveal this. It is known that substances
which reach the intraventricular cerebrospinal fluid often
reach the periventricular brain parenchyma, including the
hippocampus, so eventual parenchymal delivery cannot
be ruled out by these results[12,13,25]. Macromolecules
reaching the CSF characteristically penetrate into periven-
tricular brain parenchyma because the gap junctions
between the ependymal cells lining the ventricles are
"leaky", thus the popularity of intracerebroventricular
delivery to bypass both the BBB and the BCSFB[12,13,30].
Alternatively, it is likely that some of the physiologic
effects of perispinal etanercept are mediated primarily at
the level of the choroid plexus. Further study will be nec-
essary to define the sites of action of etanercept in the AD
brain, the effects of etanercept on the choroid plexus in
AD, and to characterize the brain parenchymal distribu-
tion of etanercept after CSF delivery.
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